Italia markets closed

Dow Jones
39.832,73
+274,62(+0,69%)
Nasdaq
16.726,19
+215,01(+1,30%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0881
+0,0060(+0,55%)
Bitcoin EUR
60.481,10
+4.056,86(+7,19%)
CMC Crypto 200
1.381,78
+113,83(+8,98%)

NVCR Jul 2024 20.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,9000

-0,1500

(-7,32%)

In data: 09:42AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in